Artwork

Content provided by Bell Direct. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Bell Direct or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

From the helm: Cyclopharm's (ASX:CYC) MD & CEO, James McBrayer

5:57
 
Share
 

Manage episode 284144805 series 2611018
Content provided by Bell Direct. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Bell Direct or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

In this instalment of our From the helm series, Bell Direct’s Jessica Amir speaks to Cyclopharm's (ASX:CYC) MD & CEO, James McBrayer.
Cyclopharm is a little known Aussie company. Its medical technology is used in 60 countries around the world to help doctors identify lung capacity, as well as find potential blood clots. With earnings mostly coming from Europe, CYC's US journey gathers momentum with USFDA approval looming. The US is home to the world's largest nuclear medicine market.
In this video James discusses:
- (0:31) What CYC does & its "imminent" entry into the US
- (1:11) Key catalysts to drive share price growth
- (1:47) Commercialising the product in the US
- (2:46) CYC's product being endorsed to help fight COVID-19 in the US
- (3:31) How the company has reduced its risks
- (4:56) After a 110% rise in share price last year, what can investors expect for the year ahead?

  continue reading

57 episodes

Artwork
iconShare
 
Manage episode 284144805 series 2611018
Content provided by Bell Direct. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Bell Direct or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

In this instalment of our From the helm series, Bell Direct’s Jessica Amir speaks to Cyclopharm's (ASX:CYC) MD & CEO, James McBrayer.
Cyclopharm is a little known Aussie company. Its medical technology is used in 60 countries around the world to help doctors identify lung capacity, as well as find potential blood clots. With earnings mostly coming from Europe, CYC's US journey gathers momentum with USFDA approval looming. The US is home to the world's largest nuclear medicine market.
In this video James discusses:
- (0:31) What CYC does & its "imminent" entry into the US
- (1:11) Key catalysts to drive share price growth
- (1:47) Commercialising the product in the US
- (2:46) CYC's product being endorsed to help fight COVID-19 in the US
- (3:31) How the company has reduced its risks
- (4:56) After a 110% rise in share price last year, what can investors expect for the year ahead?

  continue reading

57 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide